kv

Kv3 modulator 1 is an imidazolidinedione-type orthosteric modulator of Kv3 voltage-gated potassium channels. Kv3 modulator 1 reverses mechanical hyperalgesia in rat models of neuropathic and inflammatory pain, with rapid onset and sustained, dose-dependent effects. Kv3 modulator 1 can be used to study the mechanisms underlying inflammatory pain and neurological disorders such as epilepsy and schizophrenia.

Kv3 modulator 2 is a potent Kv3 channels modulator.has analgesic activity and is used in the prophylaxis or treatment of related disorders.

Kv3 modulator 3 is a selective modulator of Kv3.1 and/or Kv3.2 and/or Kv3.3 channels .has analgesic activity for use in the prophylaxis o or treatment of pain.

Kv3 modulator 4 is a cyclobutyl-structured modulator of Kv3.1 (pEC50=5.45) and Kv3.2 channels.

Kv3 channel protein is expressed by parvalbumin (PV)-containing pallidal neurons.Kv3, Channel Containing Protein (567-585) corresponds to amino acids 567 to 585 fragment of the Kv3.1b channel containing protein.

Kv2-IN-A1 is an inhibitor of Kv2.1 and Kv2.2.

Oxybutynin chloride (Oxybutynin HCl) is an anticholinergic medication used to relieve urinary and bladder difficulties. It competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor.

Oxybutynin (Ditropan) is a synthetic anticholinergic agent that is used for treatment of urinary incontinence and overactive bladder syndrome.

ApolipoproteinKV domain (67-77) is an 11-amino-acid peptide isolated from the KV domain of human apolipoprotein a (ApoA), known for its anti-angiogenic and anti-tumor activities. It targets the angiogenesis c-Src/ERK pathway by blocking activation signals received from vascular endothelial growth factor (VEGF). ApolipoproteinKV domain (67-77) is applicable in cancer research.

Kv1.5-IN-IIII is a potent inhibitor of Kv1.5.

Kv7.2/Kv7.3 agonist 1 (Compound 16) is an orally effective agonist for the KV7.2/7.3 channels (KV7.2/7.3 channel/KCNQ2/3) with an EC50 of 1.03 μM. This compound demonstrates analgesic effects in mouse models of chronic constriction injury (CCI) and Streptozotocin-induced diabetic peripheral neuropathy (DPNP), with ED50 values of 12.02 mg/kg and 9.63 mg/kg, respectively.

cis-KV1.3-IN-1, also known as Compound cis-18, is the cis-isomer of KV1.3-IN-1 and functions as an inhibitor of the KV1.3 channel. In Xenopus laevis oocytes expressing human hKV1.3, cis-KV1.3-IN-1 (10 μM) achieves an inhibition rate of 25.53% against KV1.3.

KV1.3-IN-2 (Compound I) selectively inhibits the kv1.3 potassium channel without affecting the hERG channel. It is applicable in research related to immune-associated diseases such as psoriasis, rheumatoid arthritis, and systemic lupus erythematosus.

Kv7.2/Kv7.3 modulator-2 (compound 7d) is a Kv7.2/Kv7.3 channel modulator with a pEC50 value of 7.42 for activating the Kv7.2/3 channels. This compound is applicable in the research of epilepsy, depression, brain injury, and pain.

Kv7.2/Kv7.3 modulator-1 (compound 6a) acts as a modulator for Kv7.2/Kv7.3 channels, with a pEC50 value of 7.96 for opening these channels. Kv7.2/Kv7.3 modulator-1 is applicable in research related to epilepsy, depression, brain injury, and pain.

Kv7.2/Kv7.3 activator-2 is a blood-brain barrier-penetrating activator of Kv7.2/Kv7.3 channels with an EC50 of 0.25 μM. This compound exhibits excellent photostability and demonstrates potent anticonvulsant effects in acute epilepsy mouse models induced by maximal electroshock (MES) and sc-pentylenetetrazol (sc-PTZ).

Kv3.1 modulator 2 is an agent that regulates Kv3.1 channels, exhibiting an EC50 value of 68 nM.

Kv7.2 activator-1 (Compound 8) is an activator of Kv7.2/3 channels with an EC50 of 178 nM. It has a relatively long half-life of 120 minutes in human liver microsomes (HLM).

Kv7.2/Kv7.3 activator-3 (GRT-X) is an orally active activator of Kv7.2/Kv7.3 channels and the TSPO. It activates Kv7.2/Kv7.3, Kv7.4, and Kv7.5 with EC50 values of 0.37, 2.06, and 0.75 μM, respectively, and binds to TSPO with Ki values of 0.07 μM (rat membrane) and 4.60 μM (human U-118 MG cells). This compound protects motor neurons from degeneration caused by exposure to astrocyte-conditioned media from mice and humans with amyotrophic lateral sclerosis/frontotemporal dementia. Additionally, Kv7.2/Kv7.3 activator-3 stimulates axonal growth in dorsal root ganglia through TSPO and Kv7.2/3 activation and exhibits anticonvulsant effects in epilepsy models. It alleviates hyperalgesia in diabetic neuropathy patients, enhances the survival and regeneration of neurons after cervical neuropathy in rats, and accelerates the recovery of normal function in sensory and motor neurons.

KV1.3-IN-3 (Compound 13a) is a KV1.3 channel inhibitor that reduces Kv1.3 peak current amplitude by over 80%. It exhibits excellent pharmacological properties and safety, making it suitable for autoimmune disease research.

Kv7 activator-2 (A14a) is an activator of Kv7 potassium channels, useful in research on neurological disorders such as epilepsy.

Kv7.2/Kv7.3 modulator-3 (example 40 peak-1) is a selective modulator of Kv7.2/Kv7.3 channels, with an EC50 of 0.099 μM.

KV1.3-IN-1 (Compound trans-18) is a selective KV1.3 channel inhibitor with IC50 values of 230 nM in Ltk cells and 26.12 nM in PHA-activated T-lymphocytes, disrupting intracellular Ca2+ signaling and impeding T-cell activation, proliferation, and colony formation [1].

Kv3 modulator 5 (Example 5), a Kv3 channel modulator, enhances the Kv3.2 current and may be employed in research of hearing disorders [1].